Interleukin Inhibitors Market, By Type, By Route of Administration, By Application, By Distribution Channel, By Geography

Description

The global interleukin inhibitors market is estimated to be valued at USD 32.60 Bn in 2024 and is expected to reach USD 74.81 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 12.6% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 32.60 Bn
Historical Data for:	2019 To 2023	Forecast Period:	2024 To 2031
Forecast Period 2024 to 2031 CAGR:	12.60%	2031 Value Projection:	US$ 74.81 Bn

Figure. Interleukin Inhibitors Market Share (%), By Region 2024

Interleukin inhibitors are biologics that block or dampen the activity of interleukin cytokines that play important roles in triggering inflammation. These proteins act as signaling molecules that are critical in directing the movement of white blood cells to sites of injury or infection. However, excess or prolonged inflammation can cause issues. Interleukin inhibitors help control conditions driven by inappropriate or excessive immune responses by targeting specific interleukins. Some key interleukin targets include IL-17, IL-23, and IL-1B that are implicated in autoimmune diseases. The global interleukin inhibitors market has been growing steadily as new biologics gain regulatory approvals for treating various inflammatory and immune-mediated disorders.

Market Dynamics:

The global interleukin inhibitors market is driven by the increasing prevalence of immune-mediated conditions worldwide coupled with rising healthcare expenditures. In November 2024, according to the WHO estimates, around 2-3% of the global population suffers from autoimmune diseases with many cases remaining undiagnosed or untreated. Approvals of novel interleukin inhibitors for treating diseases with high unmet needs such as psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis are also boosting the market growth. However, high costs of biologics pose a major challenge for market expansion in price-sensitive developing regions. Moreover, patent cliffs of blockbuster drugs further intensify competition. Nevertheless, ongoing R&D for developing interleukin inhibitors with improved safety profiles and new therapeutic indications provide attractive opportunities for market players.

Key Features of the Study:

This report provides in-depth analysis of the global interleukin inhibitors market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global interleukin inhibitors market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include AbbVie Inc., Johnson & Johnson, Amgen Inc., Novartis AG, Sanofi S.A., GSK plc, Eli Lilly and Company, Regeneron Pharmaceuticals, Inc., Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., UCB S.A., Astellas Pharma Inc., Bayer AG, and Sandoz International GmbH

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global interleukin inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global interleukin inhibitors market

Market Segmentation

By Type Insights (Revenue, USD Bn, 2019 - 2031)
- IL-1 inhibitors
- IL-5 inhibitors
- IL-6 inhibitors
- IL-17 inhibitors
- IL-23 inhibitors
- Other types
By Route of Administration Insights (Revenue, USD Bn, 2019 - 2031)
- Oral
- Subcutaneous (SC)
- Intravenous (IV)
- Others
By Application Insights (Revenue, USD Bn, 2019 - 2031)
- Rheumatoid arthritis
- Psoriatic arthritis
- Psoriasis
- Inflammatory bowel disease (IBD)
- Asthma
- Multiple Sclerosis
- Ulcerative colitis
- Crohn's disease
- Other applications
By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
Regional Insights (Revenue, USD Bn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- AbbVie Inc.
- Johnson & Johnson
- Amgen Inc.
- Novartis AG
- Sanofi S.A.
- GSK plc
- Eli Lilly and Company
- Regeneron Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Takeda Pharmaceutical Company Limited
- Biogen Inc.
- UCB S.A.
- Astellas Pharma Inc.
- Bayer AG
- Sandoz International GmbH

Product Code: CMI7577

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Interleukin Inhibitors Market, By Type
- Global Interleukin Inhibitors Market, By Route of Administration
- Global Interleukin Inhibitors Market, By Application
- Global Interleukin Inhibitors Market, By Distribution Channel
- Global Interleukin Inhibitors Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Driver
- Restraint
- Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Interleukin Inhibitors Market, By Type, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
IL-1 inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
IL-5 inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
IL-6 inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
IL-17 inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
IL-23 inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Other types
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

5. Global Interleukin Inhibitors Market, By Route of Administration, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Subcutaneous (SC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Intravenous (IV)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Interleukin Inhibitors Market, By Application, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Rheumatoid arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Psoriatic arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Psoriasis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Inflammatory bowel disease (IBD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Asthma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Multiple Sclerosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Ulcerative colitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Crohn's disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Other applications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Interleukin Inhibitors Market, By Distribution Channel, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospital pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Retail pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Online pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Interleukin Inhibitors Market, By Region, 2019 - 2031, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2020 - 2031, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Type, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

9. Competitive landscape

AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
Sanofi S.A.
GSK plc
Eli Lilly and Company
Regeneron Pharmaceuticals, Inc.
Merck & Co., Inc.
Takeda Pharmaceutical Company Limited
Biogen Inc.
UCB S.A.
Astellas Pharma Inc.
Bayer AG
Sandoz International GmbH

10. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

11. References and Research Methodology

References
Research Methodology
About us